A protein that may make chemo work better in childhood tumors
Original title: SLFN11 enhances cisplatin sensitivity in pediatric cancer via activation of stress-response and suppression of survival pathways.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was done on cancer cells in the lab, not in children.
The short version
In the lab, turning on one protein made childhood cancer cells easier to kill with chemo.
What was studied. Researchers studied a protein called SLFN11 in three childhood cancers: Wilms tumor, osteosarcoma, and medulloblastoma. They used cancer cells grown in the lab, plus data from past patient records.
What they found. The team switched the SLFN11 protein back on in the cells. All three of the cell lines they tested became easier to kill with the chemo drug cisplatin. The cells also became easier to kill with a drug called talazoparib. When the team looked at past patient data, the protein linked to outcomes in different ways depending on the cancer type. In some it looked helpful, in some harmful, and in some it made no difference.
What this means, and what it doesn't
What it could mean: One day, doctors may be able to check this protein to help guess how well chemo will work. It may also point to new ways to fight chemo that stops working. It does not change treatment today.
What it doesn't mean: This does not mean a new treatment is coming soon. The work was done on cancer cells in dishes and on old patient records. No child was given a new drug in this study. There is no new medicine here, and this is not a cure. Early lab results often do not hold up when tested in people.
Source: PubMed, September 2, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.